Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 17/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12236445 | 0.89 | GPR119 (0.66) | GPR119CYP2C9PIK3CD | |
| SCHEMBL12236465 | 0.86 | GPR119 (0.56) | GPR119CYP2C9KCNH2 | |
| SCHEMBL13058678 | 0.86 | GPR119 (0.63) | GPR119CYP2C9KCNH2 | |
| SCHEMBL12236406 | 0.85 | GPR119 (0.64) | GPR119CYP2C9KCNH2 | |
| SCHEMBL12261635 | 0.85 | GPR119 (0.57) | GPR119CYP2C9KCNH2 | |
| SCHEMBL288503 | 0.85 | GPR119 (0.57) | GPR119CYP2C9KCNH2 | |
| SCHEMBL3240385 | 0.85 | PIK3CD (0.53) | GPR119PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL12236489 | 0.82 | GPR119 (0.55) | GPR119CYP2C9PIK3CD | |
| SCHEMBL14476219 | 0.82 | GPR119 (0.55) | GPR119CYP2C9KCNH2 | |
| SCHEMBL20375463 | 0.81 | GPR119 (0.71) | GPR119CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722882-B2 | Pyrimidine derivatives as GPCR modulators for use in the treatment of obesity and diabetes | MERCK SHARP & DOHME CORP. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722882-B2 | Pyrimidine derivatives as GPCR modulators for use in the treatment of obesity and diabetes | MERCK SHARP & DOHME CORP. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20110263570-A1 | PYRIMIDINE DERIVATIVES AS GPCR MODULATORS FOR USE IN THE TREATMENT OF OBESITY AND DIABETES | SCHERING CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263570-A1 | PYRIMIDINE DERIVATIVES AS GPCR MODULATORS FOR USE IN THE TREATMENT OF OBESITY AND DIABETES | GPR119, GCGR, GPR65 | GPR119 1/4885CYP2C9 1648/4885KCNH2 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.